Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KCNJ1 | P48048 | 10/20 | 0.34 |
| ▸ | F11 | P03951 | 2/20 | 0.33 |
| ▸ | KLK1 | P06870 | 2/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4434027 | 0.93 | KCNH2 (0.46) | KCNH2MAOBKLKB1MAOACYP2C19 | |
| SCHEMBL14069354 | 0.90 | KCNH2 (0.36) | KCNH2MAOBKLKB1MAOACYP2C19 | |
| SCHEMBL9968665 | 0.89 | KCNH2 (0.43) | KCNH2KLKB1KCNJ1F11KLK1 | |
| SCHEMBL9968684 | 0.85 | TDO2 (0.43) | KCNH2MAOBMAOACYP2C19EGLN1 | |
| SCHEMBL9968532 | 0.84 | KCNH2 (0.40) | KCNH2MAOBMAOACYP2C19EGLN1 | |
| SCHEMBL9930329 | 0.84 | KCNJ1 (0.35) | KCNH2MAOBKLKB1MAOAKCNJ1 | |
| SCHEMBL14069844 | 0.84 | KCNH2 (0.40) | KCNH2MAOBMAOACYP2C19EGLN1 | |
| SCHEMBL13429617 | 0.83 | KCNH2 (0.42) | KCNH2KCNJ1F11EGLN1 | |
| SCHEMBL9930487 | 0.83 | MAOA (0.41) | MAOA | |
| SCHEMBL14069347 | 0.83 | MAOA (0.41) | MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | NISCH, NOD1, NQO1 | KCNH2 1295/4885MAOB 761/4885KLKB1 3350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.